von Willebrand disease (vWD) is the most common type of autosomally inherited bleeding disorder affecting up to 1% of the world's population. The disease represents a range of quantitative and qualitative pathologies of the adhesive glycoprotein, von Willebrand factor (vWF). Since symptoms are often mild, a significant majority of patients remain undiagnosed. In the hemostasis laboratory, the measurement of vWF antigen and ristocetin cofactor activity is key components in the diagnostic algorithm for vWD. With all forms of vWD, however, bleeding episodes can be severe and may require treatment, particularly during or following surgery or dental work. The primary care physician can and should play a role in recognizing the signs and symptoms of vWD and in referring patients for proper management. The treatment of bleeding in vWD involves the use of desmopressin and plasma-derived vWF concentrates and a variety of adjunctive agents. This article gives a detailed description of the case report on a 5-year-old boy who presented with vWD in dental clinic and also imparts the knowledge on back ground, pathophysiology, classification, diagnostic measures and treatment modalities of this fatal bleeding disorder from dental perspective.
the recognized autosomal inheritance pattern in his study of other family members, von Willebrand named the disorder 'Hereditary pseudohemophilia'. 1 This newly discovered malady, unlike hemophilia, affected both sexes. It became known as von Willebrand disease (vWD), which is the most common genetic coagulation disorder affecting 1 to 2% of the population worldwide. Gingival bleeding and epistaxis are frequently encountered in the affected individuals.
von WILLEBRAnD FACToR GEnE AnD PRoTEIn
The 175-kb von Willebrand factor (vWF) gene is located on the short arm of chromosome 12 and comprises 52 exons. The vWF gene sequence is replicated in part by a partial vWF pseudogene on chromosome 22. This evolutionary remnant recapitulates exons 23 to 34 of the vWF gene with 3% variance, a fact that significantly complicates the genetic analysis of this central region of the vWF gene. The 9-kb vWF transcript encodes a pre-pro-vWF protein of 2813 amino acids. The protein undergoes extensive post-translational modifications, including the removal of leader and propeptide sequences, dimer and eventual multimer generation, and the addition of many N-linked and O-linked carbohydrate structures. A recently revised annotation of the vWF protein structure indicates that whereas the platelet-and collagen-binding. A domains of the protein form globular-like structures, a series of repetitive vWC domains toward the C-terminus provide the protein with increased length and flexibility, thus facilitating the transition between compact and extended conformations under conditions of shear stress in the vasculature. 3 von Willebrand desease is a result of either quantitative or qualitative defects in the vWF. The vWF is produced in the endothelial cells and bone marrow megakaryocytes and consists of multimers that are stored in platelet alpha granules and in Weibel-Palade bodies of endothelial cells. The vWF plays a crucial role in both primary and secondary hemostasis. In primary hemostasis, vWF facilitates platelet adhesion to sites of vascular injury by binding to platelets at the glycoprotein Ib (GPIb) receptor. To achieve secondary hemostasis, vWF binds and stabilizes factor VIII (FVIII), thus preventing its circulatory clearance and reabsorption. [4] [5] [6] CLASSIFICATIon AnD PATHoPHYSIoLoGY (Table 1) 7,8
Diagnosis
Diagnosis depends on the demonstration of an abnormality in one or more of the following tests: vWF activity, vWF antigen (vWF:Ag), FVIII activity, bleeding time and optionally vWF multimers and ristocetin-induced platelet aggregation (RIPA). 9 von Willebrand factor activity is also known as ristocetin cofactor activity (vWF:RCo). Ristocetin is an antibiotic derived from the Actinomycete Nocardia lurida. It binds both vWF and platelet GPIb causing agglutination of formalinized platelets, which can be quantified and compared to a standard curve to obtain ristocetin cofactor activity. Plasma vWF antigen is measured by ELISA or latex bead assay. FVIII activity can be detected by one stage coagulation assay using FVIII deficient plasma. Bleeding time becomes helpful if it comes abnormal. von Willebrand factor multimers are measured using electrophoresis. Ristocetin-induced platelet aggregation measures affinity of vWF to GPIb by limiting [ristocetin] . It is used to diagnose type IIB variant. 
CASE REPoRT
A 5-year-old male patient, reported to the dental OPD with a chief complaint of bleeding from gums since 4 days. His history (in his mother's words) included bleeding that occurred from gums spontaneously after taking food, presence of clot in mouth, easy bruising tendencies which was managed symptomatically. History of similar incidents also reported. There was no history of pain, pressure sensation, paresthesia, difficulty in eating, swallowing, increased or decreased salivation, pus discharge, trauma or infection. This was his first dental visit. His medical history revealed that he was a known case of vWD. In his first visit (8 months , direct smear showed adequate platelets of normal morphology in clumps, and vWF assay 9.8% (47-197). His family history revealed his younger brother (1 year old) suffered from the same disease. His parents had non-consanguineous marriage. Birth history was uneventful. Personal history revealed that he attained milestones at appropriate age, immunization was up to date. He was predominantly a nonvegetarian, with no deleterious habits and used to brush his teeth once daily with tooth brush and paste in horizontal direction.
On general physical examination, he was conscious and cooperative, moderately built and nourished, well oriented with time, place and person. All vital signs were within the normal limits. Height of 96 cm and weight of 13 kg were recorded. There were no signs of pallor, icterus, cyanosis, clubbing, lymphadenopathy and edema. On extraoral examination, he had mesocephalic head, straight profile and competent lips. His eyes, ears, nose, temporomandibular joint (TMJ), skin over the face, hair and regional lymphnodes showed no abnormalities. On intraoral soft tissue examination, labial mucosa, buccal mucosa, vestibular area, frenal attachment, retromolar area, tonsils, hard palate, soft palate and tongue revealed no abnormalities, except bleeding from gingiva. On intraoral hard tissue examination, there was dental caries in relation to (irt) 54, 55, 64, 75, 84, 85 (Figs 1 and 2 ). There was mild amount of stains and deposits. The oral hygiene index according to Green and Vermillion was found to be good. On local examination of the lesion, intraoral soft-tissue inspection revealed, bleeding from gingival region and blood clots in mouth irt 75, 84, 85 regions (Fig. 2) . Patient spited clot from mouth frequently. Intraoral hard tissue inspection revealed, dental caries involving enamel, dentin and pulp irt 64, 75 and dental caries involving enamel and dentin irt 54, 55, 84, 85. On palpation, blood clots can be removed using a probe from teeth. Teeth were tender. Hence based on the history given by the patient's guardian and clinical examination carried out, a provisional diagnosis of von Willebrand disease with bleeding, chronic pulpitis irt 64, 65, 75, 85 and dental caries irt 54, 55, 84 was given. Further investigations were carried out on admission to rule out other clotting disorders (Table 2) . Based on the reported history, clinical and laboratory findings a final diagnosis of vWD with intraoral bleeding was made. Treatment planned in this case included management of bleeding and restoration of decayed teeth. Treatment rendered was, patient referred to the department of pediatrics for the management of the bleeding which included: frozen fresh plasma transfusion-1 pint 150 ml @ 7.5 ml/hr over 2 hours, injection and Lasix 15 mg IV stat mid transfusion. Follow-up was done after 2 weeks of episode. Patient did not show any signs or symptoms of bleeding (Figs 3 and 4) . Patient kept on regular follow-ups and medicated for tablet tranexa 500 mg (1/2 tid) (100 mg/kg/dose) in similar incidents.
DISCuSSIon
Contrary to other rare diseases, over the last few decades vWD has benefited from a greater understanding of the causes and mechanisms responsible for its development as well as of the molecular and physiological characteristics of the disease and its proper diagnostic and clinical management. This has undoubtedly aided in the design of highly appropriate treatment schedules. Therapies to prevent or control bleeding in persons with vWD follow three general strategies. The first strategy is to increase the plasma concentration of vWF by releasing endogenous vWF stores through stimulation of endothelial cells with desmopressin. The second approach is to replace vWF by using human plasma-derived, viral-inactivated concentrates. The third strategy uses agents that promote hemostasis and wound healing but do not substantially alter the plasma concentration of vWF. The three treatment options are not mutually exclusive, and patients may receive any one or all three classes of agents at the same time. The appropriateness of therapeutic choice depends on the type and severity of vWD, the severity of the hemostatic challenge, and the nature of the actual or potential bleeding.
nonreplacement Therapy with Desmopressin to elevate vWF
Desmopressin (DDAVP) is a synthetic derivative of the antidiuretic hormone, vasopressin. The mechanism by which desmopressin increases plasma concentration of vWF is through cyclic adenosine monophosphate (cAMP)-mediated release of vWF from endothelial cell Weibel-Palade bodies. 13 The mechanism for the rise in FVIII was thought to be due to its consequent stabilization in plasma FVIII levels. 14 ).
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Therapies to elevate vWF: Replacement Therapy
Replacement therapy aims at correcting vWF deficiency, allowing platelet adhesion and aggregation, and increasing potentially low FVIII concentrate (FVIII:C) level. They are lyophilized concentrate of purified vWF and FVIII contains other plasma proteins including fibrinogen and albumin. The concentrates thought to be most useful for the management of vWD unresponsive to DDAVP were BPL 8Y, Haemate-P (2.5 IU vWF:RCo for each unit of (FVIII:C), Alphanate (0.6 IU vWF:RCo for each unit of FVIII:C), VHP-vWF concentrate and cryoprecipitate.
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oTHER THERAPIES FoR vWD Antifibrinolytics
The antifibrinolytic drugs aminocaproic acid and tranexamic acid are agents that inhibit the conversion of plasminogen to plasmin, inhibiting fibrinolysis and thereby helping to stabilize clots that have formed. The drugs can be used orally or iv to treat mild mucocutaneous bleeding in patients with vWD. 21 In patients with mild-to-moderate vWD, tranexamic acid given topically in the oral cavity (swish and swallow or spit) every 6 hours has been used for prophylaxis in dental surgery, in combination with applied pressure, other topical agents and suturing of surgical sites.
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Topical Agents
Topical bovine thrombin is an aid to hemostasis for topical therapy of accessible minor bleeding from capillaries and small venules. Fibrin sealant [Tisseel VH (Baxter)], consisting of human thrombin, fibrinogen concentrate and bovine aprotinin] is indicated as an adjunct to hemostasis in certain surgical situations, but it is not effective for the treatment of massive and brisk arterial bleeding. Fibrin sealants have been used with good results as adjunctive therapy for dental surgery in persons with hemophilia or vWD. Topical collagen sponges are also approved for control of bleeding wounds.
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Advanced Therapies 29 Topical agents, such as fibrin sealant or bovine thrombin, may be useful adjuncts for oral surgery in persons with vWD. Careful attention to hemostasis of an extraction socket and to suturing of sockets is also important in oral surgery in persons with vWD (grade C, level IV). 22 For fillings done under infiltration with local anesthetic, treatment with DDAVP or concentrates is not needed. Treatment should be given if an inferior dental block is to be used (grade C, level IV). 28 In responsive patients a single dose of DDAVP given with tranexamic acid is usually sufficient to cover dental extractions. Treatment should be monitored at least with a FVIII:C assay unless DDAVP has been shown to be effective on previous occasions. If DDAVP cannot be used a single dose of a vWF containing concentrate can be used aiming to achieve 50 IU dL -1 VWF:RCo. Tranexamic acid should be given orally (starting before treatment) and/or as a mouthwash for 5 days afterwards.
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ConCLuSIon
Understanding the underlying pathophysiology of vWD, its subtypes, and diagnostic tests is important. Collaboration with a hematologist is crucial. History of excessive bleeding, especially after tooth extraction, should be given its due attention. The course of treatment would depend on the type of vWD defect and the extent of surgery. To maintain primary hemostasis, the presence of functional vWF and platelets is necessary, whereas in secondary hemostasis FVIII is required to participate in the intrinsic clotting pathway. Finally, 'although optimism is clearly justified in patients with vWD, fantasy is best avoided in order to not raise false expectations in the patients suffering from this rare disease that may be subject to either curative or palliative treatment'.
